Clinical trials for Classic hairy cell leukemia
18 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPHASE1, PHASE2NCT06965114Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaNational Cancer Institute (NCI) · PI: Seema A Bhat
- RECRUITINGN/ANCT06781515Assessment of Disease Burden in Hairy Cell LeukemiaIRCCS Azienda Ospedaliero-Universitaria di Bologna · PI: Pier Luigi Zinzani, MD
- RECRUITINGPhase 2NCT06311227Venetoclax for the Treatment of Patients With Relapsed Hairy Cell LeukemiaNational Cancer Institute (NCI) · PI: Robert J Kreitman
- RECRUITINGNCT06774677Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care ManagementIRCCS Azienda Ospedaliero-Universitaria di Bologna · PI: Lucia Catani, PhD
- RECRUITINGNCT06764524Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care ManagementIRCCS Azienda Ospedaliero-Universitaria di Bologna · PI: Lucia Catani, PhD
- RECRUITINGPhase 2NCT06561360A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)Memorial Sloan Kettering Cancer Center · PI: Jae Park, MD
- RECRUITINGPhase 1NCT06340737AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell LymphomasStanford University · PI: Matthew Frank, MD, PhD
- RECRUITINGPhase 1NCT04815356Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and VariantNational Cancer Institute (NCI) · PI: Robert J Kreitman, M.D.
- RECRUITINGPhase 2NCT04322383Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and VariantNational Cancer Institute (NCI) · PI: Robert J Kreitman, M.D.
- RECRUITINGPhase 2NCT04324112Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCLNational Cancer Institute (NCI) · PI: Robert J Kreitman, M.D.
- ACTIVE NOT RECRUITINGPhase 1NCT03805932Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell LeukemiaNational Cancer Institute (NCI) · PI: Robert J Kreitman, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT03410875A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell LeukemiaMemorial Sloan Kettering Cancer Center · PI: Jae Park, MD
- ACTIVE NOT RECRUITINGPhase 2NCT01841723Ibrutinib in Treating Patients With Relapsed Hairy Cell LeukemiaNational Cancer Institute (NCI) · PI: Kerry A Rogers
- RECRUITINGNCT02560883Hairy Cell Leukemia Patient Data RegistryOhio State University Comprehensive Cancer Center · PI: Michael Grever, MD
- ACTIVE NOT RECRUITINGPhase 2NCT01059786Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaNational Cancer Institute (NCI) · PI: Robert J Kreitman, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT00923013Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell LeukemiaNational Cancer Institute (NCI) · PI: Robert J Kreitman, M.D.
- RECRUITINGPhase 2NCT00412594Cladribine and Rituximab in Treating Patients With Hairy Cell LeukemiaM.D. Anderson Cancer Center · PI: Farhad Ravandi-Kashani
- RECRUITINGPHASE2, PHASE3NCT02131753Therapy Optimisation for the Treatment of Hairy Cell LeukemiaUniversity of Giessen · PI: Mathias J Rummel, Prof. Dr.